Literature DB >> 15208140

Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary findings.

Constantinos T Sofocleous1, Kenneth M Klein, Basil Hubbi, Karen T Brown, Stanley H Weiss, George Kannarkat, Clay R Hinrichs, Daniel Contractor, Philip Bahramipour, Allison Barone, Stephen R Baker.   

Abstract

OBJECTIVE: Our aim was to evaluate the histologic characteristics of tissue extracted on the probe immediately after radiofrequency ablation of malignant tumors in the liver.
MATERIALS AND METHODS: From April to December 2001, 20 radiofrequency ablations were performed in 19 patients with primary (n = 17) and metastatic (n = 2) liver masses. Track ablation according to device protocol was performed after each ablation. Tissue was adherent to the probe after all radiofrequency probe passes. All pieces of tissue found on the probe were collected and preserved in formalin.
RESULTS: Tissue was examined by the study pathologist. In eight (40%) of 20 specimens, coagulation necrosis was present. In five (25%) of 20 specimens, possibly nonviable tissue was extracted, although some cell characteristics were identified. In seven (35%) of 20 specimens with hepatocellular carcinoma, possibly viable tissue was found. Five specimens were identified as hepatocellular carcinoma, and two, as cirrhotic nodules.
CONCLUSION: Histopathologic evaluation of the tissue extracted on the radiofrequency probe after ablation is feasible. This study showed that coagulation necrosis was clearly present in at least 40% of the patients, which proves that nonviable tissue can be seen immediately after ablation. Whether this pathologic finding has prognostic value is not known.

Entities:  

Mesh:

Year:  2004        PMID: 15208140     DOI: 10.2214/ajr.183.1.1830209

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

1.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

Review 2.  Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease.

Authors:  Elena Nadia Petre; Constantinos Sofocleous
Journal:  Visc Med       Date:  2017-02-03

3.  18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.

Authors:  Francois Cornelis; Vlasios Sotirchos; Elena Violari; Constantinos T Sofocleous; Heiko Schoder; Jeremy C Durack; Robert H Siegelbaum; Majid Maybody; John Humm; Stephen B Solomon
Journal:  J Nucl Med       Date:  2016-02-23       Impact factor: 10.057

4.  Re: Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours.

Authors:  C T Sofocleous; N Petre; K Manova-Todorova; L Petrovic; M Gonen
Journal:  Dig Surg       Date:  2009-11-13       Impact factor: 2.588

5.  Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases.

Authors:  Francois H Cornelis; Elena N Petre; Efsevia Vakiani; David Klimstra; Jeremy C Durack; Mithat Gonen; Joseph Osborne; Stephen B Solomon; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2018-02-09       Impact factor: 10.057

6.  Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.

Authors:  Vlasios S Sotirchos; Lydia M Petrovic; Mithat Gönen; David S Klimstra; Richard K G Do; Elena N Petre; Alessandra R Garcia; Afsar Barlas; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Lynn A Brody; Ronald P DeMatteo; Nancy E Kemeny; Stephen B Solomon; Katia O Manova-Todorova; Constantinos T Sofocleous
Journal:  Radiology       Date:  2016-03-24       Impact factor: 11.105

7.  Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies.

Authors:  Constantinos T Sofocleous; Sandeep Garg; Lydia M Petrovic; Mithat Gonen; Elena N Petre; David S Klimstra; Stephen B Solomon; Karen T Brown; Lynn A Brody; Ann M Covey; Ronald P Dematteo; Lawrence Schwartz; Nancy E Kemeny
Journal:  Ann Surg Oncol       Date:  2012-07-03       Impact factor: 5.344

8.  Multimodality imaging to assess immediate response to irreversible electroporation in a rat liver tumor model.

Authors:  Yue Zhang; Sarah B White; Jodi R Nicolai; Zhuoli Zhang; Derek L West; Dong-Hyun Kim; A Lee Goodwin; Frank H Miller; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

9.  Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases.

Authors:  Sho Fujisawa; Yevgeniy Romin; Afsar Barlas; Lydia M Petrovic; Mesruh Turkekul; Ning Fan; Ke Xu; Alessandra R Garcia; Sebastien Monette; David S Klimstra; Joseph P Erinjeri; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous
Journal:  Cytotechnology       Date:  2013-09-25       Impact factor: 2.058

10.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.